Loading
Life sciences · Journal article
Frontiers in Immunology · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Chronic low-grade inflammation (CLGI) is a major feature of metabolic syndrome (MetS), and the intestinal mucosa is an important site where microbial metabolites interact with host immunity. Intestinal lamina propria macrophages (LpMs) maintain mucosal tolerance, barrier homeostasis, and antimicrobial defense, and their phenotype and metabolism are altered in obesity and related metabolic disturbances. Short-chain fatty acids (SCFAs), generated mainly by microbial fermentation of dietary fiber, influence macrophage function through intracellular metabolism, G protein-coupled receptor signaling, and histone deacetylase inhibition. Butyrate is the best-characterized SCFA in this context and regulates glycolysis, mTOR-associated metabolism, antimicrobial responses, and HDAC-dependent inflammatory programs. Acetate and propionate also affect inflammasome activity, cytokine production, receptor signaling, and cellular metabolism. These mechanisms connect microbial metabolism with intestinal inflammation, epithelial barrier function, and systemic metabolic homeostasis. In obesity and insulin resistance, colonic macrophage recruitment and metabolic remodeling are closely associated with disease progression, whereas macrophage-related effects in metabolic dysfunction-associated steatotic liver disease and hypertension involve broader gut–liver, vascular, and renal pathways. Human studies of dietary fiber, microbiota-directed interventions, and SCFA delivery show variable cardiometabolic effects, with outcomes influenced by formulation, route, and baseline metabolic state. Given that most current mechanisms are derived from extraintestinal macrophages and in situ evidence from the human gut remains scarce, this narrative review summarizes the homeostatic biology of intestinal macrophages, the pathways through which SCFAs regulate their immunometabolism, the context-dependent relevance of this axis across MetS components, and the barriers to clinical translation.